ECX Share Price Performance
€0
0.00 (0.00%)
Price €0
Share Pricen/a
Epigenomics AG Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
ECX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Epigenomics AG Key Details
Last Reported Earnings
Dec 31, 2023
Next Reporting Earnings
Sep 30, 2024
- -5.07
- 83.22%
- -1,315.79%
- -148.3%
About ECX
- Founded
- 1998
- Employees
- 18
- CEO
- WebsiteView website
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. The company was founded in 1998 and is headquartered in Berlin, Germany.
